Table 2 Characteristics for the full and inverse probability of treatment-weighted cohort with mortality as outcome
Full cohort | IPT-weighted cohort | |||||
|---|---|---|---|---|---|---|
Early RRT (n = 621) | Late RRT (n = 592) | SMD | Early RRT (n = 621) | Late RRT (n = 592) | SMD | |
Demographics | ||||||
Age, years, median (IQI) | 67.7 (58.5–75.3) | 69.0 (59.3–75.8) | −0.09 | 68.1 (59.5–76.6) | 68.7 (58.1–75.5) | 0.03 |
Male sex, n (%) | 419 (65.5) | 419 (70.8) | −0.11 | 425 (68.5) | 401 (67.7) | 0.02 |
Surgical status, n (%) | ||||||
Nonsurgical | 229 (36.9) | 281 (47.5) | −0.22 | 261 (42.1) | 248 (42.0) | −0.02 |
Noncardiac surgery, elective | 37 (6.0) | 47 (7.9) | −0.08 | 42 (6.7) | 43 (7.3) | −0.02 |
Noncardiac surgery, acute | 67 (10.8) | 66 (11.1) | −0.01 | 67 (10.8) | 65 (11.0) | −0.00 |
Cardiac surgery, elective | 100 (16.1) | 66 (11.1) | 0.14 | 84 (13.5) | 74 (12.5) | 0.03 |
Cardiac surgery, acute | 188 (30.3) | 132 (22.3) | 0.18 | 167 (26.8) | 161 (27.3) | −0.01 |
SOFA score, mean (SD) | 5.5 (2.4) | 4.8 (2.5) | 0.29 | 5.2 (2.5) | 5.2 (2.5) | 0.01 |
ICU treatments, n (%) | ||||||
Vasopressors or inotropes | 555 (89.4) | 491 (82.9) | 0.19 | 543 (87.4) | 513 (86.6) | 0.02 |
Mechanical ventilation | 475 (76.5) | 420 (70.9) | 0.13 | 460 (74.0) | 441 (74.5) | −0.01 |
Extracorporeal membrane oxygenation | 84 (13.5) | 40 (6.8) | 0.23 | 67 (10.7) | 65 (11.0) | −0.01 |
Laboratory values | ||||||
Creatinine, baseline, μmol/L, median (IQI) | 94.9 (82.0–117.0) | 90.7 (73.7–102.2) | 0.19 | 93.2 (76.8–115.0) | 92.0 (76.8–111.7) | 0.01 |
Potassium, mmol/L, median (IQI) | 4.4 (3.9–5.0) | 4.5 (4.1–5.1) | −0.17 | 4.4 (4.0–5.0) | 4.5 (4.0–5.0) | −0.04 |
Sodium, mmol/L, mean (SD) | 139.3 (7.0) | 138.8 (7.2) | 0.06 | 138.9 (7.1) | 138.8 (7.0) | 0.00 |
Preadmission morbidity, n (%) | ||||||
Renal disease | 178 (28.7) | 208 (35.1) | −0.14 | 198 (31.9) | 188 (31.8) | 0.00 |
Diabetes | 101 (16.3) | 107 (18.1) | −0.05 | 108 (17.4) | 104 (17.5) | −0.00 |
Congestive heart disease | 180 (29.0) | 120 (20.3) | 0.20 | 161 (25.9) | 153 (25.9) | −0.00 |
Myocardial infarction | 154 (24.8) | 136 (23.0) | 0.04 | 149 (24.0) | 148 (25.0) | −0.02 |
Cerebrovascular disease | 80 (12.9) | 86 (14.5) | −0.05 | 83 (13.3) | 76 (12.9) | 0.01 |
Chronic pulmonary disease | 113 (18.2) | 90 (15.2) | 0.08 | 101 (16.3) | 92 (15.6) | 0.02 |
Liver disease | 21 (3.4) | 23 (3.9) | −0.03 | 22 (3.6) | 21 (3.5) | 0.00 |
Vascular disease | 172 (27.7) | 161 (27.2) | 0.01 | 180 (29.1) | 164 (27.7) | 0.03 |
Tumor | 68 (11.0) | 95 (16.0) | −0.15 | 85 (13.7) | 81 (13.7) | −0.00 |
Lymphoma | 9 (1.4) | 6 (1.0) | 0.04 | 8 (1.3) | 9 (1.5) | −0.01 |
Leukemia | 7 (1.1) | 5 (0.8) | 0.03 | 6 (0.9) | 7 (1.1) | −0.02 |
Metastasis | 16 (2.6) | 17 (2.9) | −0.02 | 16 (2.5) | 17 (2.9) | −0.03 |
Year of treatment, n (%) | ||||||
2005–2006 | 95 (15.3) | 149 (25.2) | −0.25 | 121 (19.5) | 115 (19.4) | −0.04 |
2007–2008 | 101 (16.3) | 120 (20.3) | −0.10 | 112 (18.0) | 106 (18.0) | −0.00 |
2009–2010 | 141 (22.7) | 93 (15.7) | 0.18 | 119 (19.1) | 119 (20.1) | −0.03 |
2011–2012 | 158 (25.4) | 94 (15.9) | 0.24 | 132 (21.3) | 124 (20.9) | 0.01 |
2013–2014 | 126 (20.3) | 136 (23.0) | −0.07 | 138 (22.1) | 128 (21.7) | 0.01 |